Study S001977

A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus on Metformin

ClinicalTrials.gov record

Registration

Registration: NCT05762471
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 142
Start: 2023-01-09
Primary completion: 2024-04-11
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions: Overweight or Obesity; Type2 Diabetes Mellitus
Interventions: DRUG:GSBR-1290; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM [42 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.